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Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune/inflammatory disease. Patients diagnosed with juvenile-
onset SLE (jSLE), when compared to individuals with adult-onset SLE, develop more severe organ involvement, increased
disease activity and greater tissue and organ damage. In adult-onset SLE, clinical characteristics, pathomechanisms,
disease progression and outcomes do not only vary between individuals and age groups, but also ethnicities.
However, in children and young people, the influence of ethnicity on disease onset, phenotype and outcome has not
been investigated in detail. In this study, we investigated clinical and laboratory characteristics in pediatric SLE patients
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from different ethnic backgrounds (White Caucasian, Asian, Black African/Caribbean) accessing data from a national cohort of
jSLE patients (the UK JSLE Cohort Study). Among jSLE patients in the UK, ethnicity affects both the disease’s clinical course
and outcomes. At diagnosis, Black African/Caribbean jSLE patients show more “classical” laboratory and clinical features
when compared to White Caucasian or Asian patients. Black African/Caribbean jSLE patients exhibit more renal involvement
and more frequently receive cyclophosphamide and rituximab. Studies targeting ethnicity-specific contributors to disease
expression and phenotypes are necessary to improve our pathophysiological understanding, diagnosis and treatment of jSLE.
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Introduction
Systemic lupus erythematosus (SLE) is a systemic auto-
immune/inflammatory condition that can affect any
organ system and result in significant damage.1,2
Approximately 15–20% of SLE patients develop their
disease in childhood or adolescence and are therefore
diagnosed with juvenile-onset SLE (jSLE).1,2 JSLE
patients exhibit more severe organ involvement,
increased disease activity and greater tissue and organ
damage, by the time of diagnosis. Children and young
people with SLE require more immune suppressive
mediation, including corticosteroids, which contributes
to increased morbidity and mortality.3–5
In jSLE we already know that clinical characteris-
tics, underlying pathomechanisms, disease progression
and outcomes vary between age groups;6 with adult
SLE cohorts demonstrating that ethnicity is also a
strong determinate of disease course and outcome.7–15
We and others previously discussed that early disease
onset, atypical or particularly severe clinical and labo-
ratory presentation may be the result of increased
genetic burden in young individuals and/or particularly
affected ethnic groups.1,16–18 Whilst it is likely that
ethnic background also contributes to age at disease
onset, clinical phenotype, treatment response and dis-
ease outcome in children and young people, this has
not been investigated in much detail to date.7–15,19,20
The aim of this study was to investigate differential
clinical and laboratory characteristics in jSLE patients
from different ethnic backgrounds (White Caucasian,
Asian, Black African/Caribbean). To achieve this, pro-
spectively collected data from a national cohort of jSLE
patients (the UK jSLE Cohort Study) was interrogated.
Methods
Participants
A total of 422 Participants of the UK jSLE Cohort
Study,21 followed between 2006–2018, aged 16 years
at the time of diagnosis and with 4 American College
of Rheumatology (ACR) classification criteria for
SLE22 were included in this study. Patient/parent
reported ethnicity information was collected using the
UK National Census categorisations.23 Eleven poten-
tial participants were excluded as they could not be
included within one of three major ethnicity groups
(White Caucasian, Asian or Black African/
Caribbean). Data of patients who were of mixed
ethnic background were grouped with those of the
associated ethnic minority group (e.g. Asian if mixed
Asian and White Caucasian ethnicity).
Data collected
Clinical, serological and treatment information collect-
ed in the UK jSLE Cohort Study was analysed, includ-
ing: 1) total 1997 ACR score including individual
domains;22 2) Systemic Lupus International
Collaborating Clinics standardised damage index
(SLICC-SDI) score;24 3) The Systemic Lupus
Erythematosus Disease Activity Index 2000 score
(SLEDAI-2K)254) paediatric British Isles Lupus
Assessment Grade 2004 numerical scores
(pBILAG2004) with individual organ/system domains
(alphabetical score A-E);26 5) key laboratory findings,
including haemoglobin levels, white cell count and dif-
ferentiation, platelets, erythrocyte sedimentation rate
(ESR), complement levels (C3, C4) and antinuclear
antibody (ANA) and anti-double-stranded DNA
(dsDNA) titres, and positivity 6) treatments used
throughout the disease course. All data was collected
at diagnosis of jSLE; items 1, 2, 3 and 5 were also
collected at the last follow-up, and the maximum
SLEDAI-2K score (item 3) was collected during the
course of the disease.
1997 ACR classification criteria data are available
for all patients in the UK jSLE Cohort study. Use of
the “new” 2019 EULAR/ACR criteria is not deemed
appropriate as we have previously shown that a signif-
icant subset of pre-pubertal SLE patients (14%)
598 Lupus 30(4)
included within the UK jSLE Cohort would not fulfil
these criteria, as they are antinuclear antibodies nega-
tive.6,27 The Systemic Lupus International
Collaborating Clinics Damage Index (SLICC-SDI) is
a measure of damage comprised of 41 components,
which help establish any long-term effect as a result
of lupus.24 The pBILAG2004 is a score used to mea-
sure disease activity in nine different organ systems in
jSLE, graded A-E. All grades are translated into a
numerical score (A¼ 12, B¼ 8, C¼ 1, D¼ 0 and
E¼ 0, maximum value 96), with scores of A or B rep-
resenting severe and moderate organ system involve-
ment respectively.28 SELENA-SLEDAI is a weighted
composite index of disease activity, considering 24 dif-
ferent items.29
Statistical analysis
Laboratory findings, total number of ACR criteria,
SLICC and pBILAG2004 scores were compared
between different ethnic groups using Kruskal-
Wallace tests cross-sectionally at diagnosis and last
follow-up. When significant differences were identified,
post-hoc testing using Dunn’s multiple comparison test
for pairwise comparisons was employed. Median
values and interquartile ranges (IQRs) are displayed
within tables. Categorical pBILAG2004 domain data
is presented as counts and percentage of patients with
active organ/system involvement for each age group
along with 95% confidence intervals. Individual
domains of the pBILAG2004 score, SLICC-SDI cate-
gories, antibody positivity on admission and treatments
used, were compared between ethnic groups using Chi-
square and Fisher’s exact tests. Where these were sig-
nificant, further Chi-square tests were used with a
Bonferroni correction. Analysis was completed using
SPSS-version 25 software (IBM SPSS).
Results
Demographics
A total of 422 patients from the UK jSLE Cohort
Study and Repository were included in this study.
219/422 (51.9%) where White Caucasian, 134/422
(31.8%) Asian, and 69/422 (16.4%) were Black
African/Caribbean. Overall, 355/422 (84%) patients
were female, with a significantly smaller proportion
of females present in the Asian group (101/134;
75.5%; p< 0.003) when compared to both the White
Caucasian (191/219; 87.2%, p¼ 0.006) and the Black
African/Caribbean group (63/69; 91.3%; p¼ 0.008).
The female:male ratio was 6.82:1 in White Caucasian,
3.16:1 in Asian and 10.5:1 in Black African/Caribbean
jSLE patients.
The median age at diagnosis was 12.2 years [10.58–
14.67]. Black African/Caribbean children were
diagnosed at a significantly younger age (12.34 [9.43–
13.72]) years than White Caucasians (13.06 [11.00–
14.92]) years (p¼ 0.021). The age at diagnosis for
Asians was not significantly different to the other eth-
nicity groups (13.02 [10.71–14.58]) years. The White
Caucasian group had a significantly longer time to
diagnosis (0.37 [0.00–14.5]) years than the Asian
group (0.26 [0.00–14.07] (p¼ 0.049). The Black
African/Caribbean group showed no significant differ-
ence in time to diagnosis with the other groups
(Supplement Table 1).
Clinical and laboratory phenotype at diagnosis
At diagnosis, median ACR and SLICC damage scores
where comparable between groups (Table 1 and
Supplement Table 2). Total numerical pBILAG2004
disease activity scores differed significantly between
the three ethnic groups [White Caucasian 9[4–16],
Asian 8[4–16], Black African/Caribbean 5[1–12];
p¼ 0.019], with pairwise testing revealing higher
scores in newly diagnosed White Caucasian group
when compared to the Black African/Caribbean
group (p¼ 0.04), and in the Asian group when com-
pared to the Black African/Caribbean group (p¼ 0.02).
SLEDAI-2K scores also followed the same pattern
[White 11[6–17], Asian 8[5–14], Black African/
Caribbean 7[2–10]; p< 0.001], with the White
Caucasian group scores being significantly higher
than the Black African/Caribbean group scores
(p< 0.001); and the Asian group scores being signifi-
cantly higher than the Black African/Caribbean group
scores (p¼ 0.039).
Comparing the pBILAG organ domain scores
between groups, the Black African/Caribbean group
had the smallest amount of constitutional symptoms
at diagnosis; post hoc analysis revealed that the Asian
group had a significantly larger amount of constitu-
tional symptoms (p¼ 0.003) (White Caucasian: 60/
219 (27.4%), Asian: 53/134 (39.6%), Black African/
Caribbean: 13/69 (18.8%); p¼ 0.005). The Asian
group had the largest amount of mucocutaneous symp-
toms at diagnosis; post hoc analysis revealed that this
was significantly higher than the mucocutaneous symp-
toms experienced in the Black African/Caribbean group
(p¼ 0.004) (White Caucasian 83/219 (37.9%), Asian:
63/134 (47%), Black African/Caribbean: 18/69
(26.1%); p¼ 0.014). The White Caucasian group had
the greatest proportion of significant musculoskeletal
activity on diagnosis; post hoc analysis revealed this
was significantly greater than the musculoskeletal symp-
toms experienced in the Black African/Caribbean
group (p¼ 0.017) (White Caucasian: 78/219 (35.6%),













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Asian: 37/134 (27.6%), Black African/Caribbean: 14/69
(20.3%); p¼ 0.037) (Table 1). Overall SLICC damage
scores and individual SLICC damage items were not
significantly different between ethnicity groups at diag-
nosis (Supplement Table 2).
At diagnosis, erythrocyte sedimentation rates (ESR)
were significantly higher in Black African/Caribbean
(45.5mm/h) jSLE patients when compared to White
Caucasians (26mm/h; p¼ 0.045) (Table 2). No differ-
ences in ESR were detected between Asians
(45.5mm/h) and the other groups. While there was a
trend towards a higher proportion of autoantibody
positive individuals among Asians and Black African/
Caribbean jSLE patients as compared to White
Caucasians, this did not reach statistical significance.
Clinical course and follow up
The length of follow-up and age at last follow-up were
comparable between the different ethnic groups (all
p>0.05) (Table 3). At the last follow-up visit, there
were no significant differences in total ACR,
SLEDAI or SLICC damage scores between the differ-
ent ethnicity groups.
Over the total follow-up period, the maximum
SLEDAI score differed between ethnic groups (White
Caucasians 14[10–20]), Asians 12[8–17]), Black African/
Caribbean 14[8–20], with post-hoc testing revealing the
maximum SLEDAI score to be significantly higher in
the White Caucasian group when compared to the
Asian group (p¼ 0.031). No significant differences
were seen in maximum total pBILAG2004 between
groups (p¼ 0.551). Looking at involvement of individ-
ual pBILAG domains over the total follow-up period,
the number of patients who developed significant con-
stitutional symptoms differed between the ethnic
groups (White Caucasian: 79/219 (36.1%), Asian: 67/
134 (50.0%), Black African/Caribbean 23/69 (33.3%);
p¼ 0.016), with post-hoc testing revealing that those of
Asian ethnicity had significantly more constitutional
involvement than White Caucasians (p¼ 0.008). The
number of patients who developed significant haema-
tological involvement also differed significantly
between ethnic groups (White Caucasians: 92/219
(42%), Asians: 59/134 (44%), Black African/
Caribbeans: 41/69 (59.4%), p¼ 0.037). Post hoc anal-
ysis revealed that the Black African/Caribbean group
had significantly greater haematological involvement
compared to the White Caucasian group (p¼ 0.01).
At the time of the patients last follow-up visits, no
difference was seen in the total SLICC SDI score or the
individual damage items between different ethnic
groups (all p>0.05, Table 4). Some laboratory findings
did vary between ethnic groups at last follow-up (Table
5). Haemoglobin levels differed between the ethnic
groups (White Caucasians 13.00 [12.10–14.10], Asians
12.50 [11.60–13.60], Black African/Caribbeans 11.70
(9.75–12.95), p< 0.001). Patients of Black African/
Caribbean ethnicity displayed the lowest haemoglobin
levels, which were significantly lower than those of the
Asian group (p¼ 0.014), although all haemoglobin
levels were within the normal range. ESR levels differed
Table 2. Laboratory features at diagnosis.




(n¼ 219) P value
Haemoglobin level (g/dl) 10.95 [9.40–12.33] 10.95 [9.25–12.30] 11.35 [10.2–12.67] 0.084
White cell count (x 109/l) 5.02 [7.67–3.97] 5.63 [8.69–4.17] 5.9 [3.92–8.18] 0.191
Platelets (x 109/l) 248.5 [183.25–311] 275 [199–377] 264 [186–331] 0.161
ESR (mm/hr) 45.5 [15.25–85.75] 45.5 [23–100.5] 26 [10–68] 0.016 (C vs
B5 0.045)
CRP 5.00 [3.00–7.00] 5.00 [5.00–7.00] 5.00 [4.00–10.00] 0.621
C3 median (g/l) 0.74 [0.45–1.2] 0.78 [0.52–1.06] 0.89 [1.11–0.55] 0.451
C4 median (g/l) 0.1 [0.06–0.21] 0.1 [0.06–0.20] 0.1 [0.05–0.16] 0.294
ANA positivity 129 (96.3%) (93.1%, 99.5%) 67 (97.1%) (93.1%, 100.0%) 202 (92.2%) (88.7%, 95.8%) 0.156
Anti-DNA antibody 87 (64.9%) (56.9%, 73.0%) 50 (72.5%) (61.9%, 83.0%) 140 (63.9%) (57.6%, 70.3%) 0.419
Anti-Smith antibody
positivity
30 (22.4%) (15.3%, 29.5%) 19 (27.5%) (17.0%, 38.1%) 43 (19.6%) (14.4%, 24.9%) 0.375
Antiphospholipid
antibody positivity
25 (18.7%) (12.1%, 25.3%) 15 (21.7%) (12.0%, 31.5%) 48 (21.9%) (16.4%, 27.4%) 0.750
Laboratory data was collected at diagnosis and median values with interquartile ranges are presented, apart from ANA positivity which is expressed as
a percentage. P values relate to Kruskal Wallace tests, comparing distribution across the three ethnic groups. Results of post-hoc pairwise comparison
tests (Dunn’s test) are indicated in curved brackets under the p value, indicating where the significant differences lie using the following codes: A¼
Asian, B¼Black African/Caribbean, C¼White Caucasian.













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































between the three ethnic groups (White Caucasians
8.00 [3.00–19.50], Asians 11.50 [6.00–28.25] and Black
African/Caribbeans 19.00 (10.25–41.50), p< 0.001),
with the levels in White Caucasians being significantly
lower than in both the Asian and Black African/
Carribean groups (p¼ 0.042 and p< 0.001 respective-
ly). Notably, at last visit, a higher number of Black
African/Caribbean (69/69, 100%) and Asian (133/
136, 99.3%) patients where ANA positive as compared
to White Caucasians (208/219, 95%; p¼ 0.019).
However, post hoc analysis revealed no significant dif-
ference between groups.
Treatment
Mycophenolate Mofetil treatment use differed between
the ethnic groups ((Asian 85/134 (63.4%), Black
African/Caribbean 45/69 (65.2%) and White
Caucasian patients 112/219 (51%), p¼ 0.027); howev-
er, post hoc testing was unable to find any significant







(n¼ 219) P value
SLICC-SDI 0 [0–1] 0 [0–1] 0 [0–1] 0.656
SLICC domain involvement
 Cataract 3 (2.2%) 0 (0%) 2 (0.9%) 0.463
 Retinal change 3 (2.2%) 1 (1.5%) 2 (0.9%) 0.574
 Cognitive 4 (3.0%) 4 (5.8%) 9 (4.1%) 0.625
 Proteinuria 7 (5.2%) 2 (2.9%) 12 (5.5%) 0.682
 Pericarditis 0 (0%) 1 (1.5%) 2 (0.9%) 0.284
 Thrombosis 2 (1.5%) 1 (1.5%) 4 (1.8%) 1.00
 Muscle atrophy 6 (4.5%) 2 (2.9%) 8 (3.7%) 0.846
 Alopecia 18 (13.4%) 9 (13.0%) 24 (11.0%) 0.760
 Gonadal failure 1 (0.7%) 3 (4.4%) 1 (0.5%) 0.052
Total SLICC-SDI values are presented as medians with interquartile ranges. Constituent damage components are
presented as a number with a percentage in the brackets.
Table 5. Laboratory findings at last visit.




(n¼ 219) P value
Haemoglobin (g/dl) 12.50 [11.60–13.60] 11.70 [9.75–12.95] 13.00 [12.10–14.10] <0.001
(A vs B 5 0.014)
White cell count
(x 109/l)
5.51 [4.23–7.14] 5.53 [3.91–7.86] 5.40 [4.20–7.11] 0.717
Platelets (x 109/l) 265 [218.00–314.75] 263 [218.50–302.00] 253 [209.75–304.00] 0.299
ESR (mm/hr) 11.50 [6.00–28.25] 19.00 [10.25–41.50] 8.00 [3.00–19.50] <0.001 (C vs A 5 0.042;
C vs B 5 <0.001)
CRP 4 [1–5] 4 [1–5] 4 [2–5] 0.141
C3 (g/l) 1.03 [0.73–1.24] 1.00 [0.87–1.21] 1.06 [0.89–1.25] 0.367





































All values laboratory titres are reported as median values with interquartile ranges. Antibody positivity variables are reported as the number of positive
patients and the associated percentage of their group with 95% confidence intervals. Results of post-hoc pairwise comparison tests (Fisher’s Exact test)
are indicated in curved brackets under the p value, indicating where the significant differences lie using the following codes: A¼Asian, B¼Black
African/Caribbean, C¼White Caucasian.
Massias et al. 603
differences. Rituximab treatment used also differed
between the three ethnic groups ((Asian 29/134
(21.6%), Black African/Caribbean 26/69 (37.7%) and
White Caucasian patients 51/219 (23.3%), p¼ 0.03)
with post-hoc testing showing Black African/
Caribbean patients having significantly greater usage
compared to Asian patients (Table 6) (p¼ 0.015).
Influence of ANA positivity
The presence ANA antibodies may discriminate
between “classical” SLE patients and such with a stron-
ger contribution of genetic factors and would not be
classified as having jSLE following the “new” 2019
ACR/EULAR criteria (e.g. likely monogenic disease
causes that may remain ANA negative at diagno-
sis).1,2,6,27 Thus, we performed sub-analysis of all sta-
tistically significant findings from above only in at
diagnosis ANA positive jSLE patients across ethnicities
at the time of diagnosis and at “last visit” (Supplement
Table 3). For most findings, differences remained
between now slightly smaller ANA positive cohorts.
Significance was lost in post hoc tests for ESR, likely
because of the reduced sample size, but trends
remained.
Discussion
In this study, we compared clinical and laboratory dis-
ease parameters, disease activity and damage measures
in jSLE patients from different ethnic groups within the
UK jSLE Cohort Study and Repository. While there
are studies available focussing on differences in disease
presentation and prognosis in adult-onset SLE popula-
tions, to our knowledge, this is the first large national
study in the context of jSLE.1,16–18
Previous reports in adult-onset SLE and relatively
small jSLE cohorts have suggested increased disease
incidence and prevalence in Black African/Caribbean
and Asian populations with higher risk of disease-
associated damage, and requirement for more aggres-
sive treatment.18–20 In line with these observations,
jSLE patients from minority ethnic backgrounds were
more prevalent in this study population as compared to
the UK national census reporting figures. 219/422
(51.9%) jSLE patients where White Caucasian, 134/
422 (31.8%) were Asian, and 69/422 (16.4%) were
Black African/Caribbean, compared with UK census
data reporting 86% of the population to be White
Caucasian, 7.5% Asian (8.0% including mixed ethnic
background), and 3.3% Black African/Caribbean (5%
including mixed ethnicity).30
Previous reports from our group and others suggest
that sex distribution in jSLE varies from that in adult-





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































develop jSLE as compared to boys, while in adult SLE
there are 9–10 females with SLE for each male. In the
UK jSLE Cohort, the female:male ratio in White
Caucasians and Asian was 6.82:1 and 3.15:1 respective-
ly, as expected in paediatric cohorts, whereas in Black
African/Caribbean patients the ratio was 10.5:1, similar
to adult-onset SLE cohorts. Puberty and increased oes-
trogen exposure are key factors in the development of
SLE,1,2,31 therefore the observation that a higher pro-
portion of girls are present amongst the Black African/
Caribbean jSLE patient group may relate to the earlier
onset of puberty in Black African/Caribbean girls,
when compared to White Caucasian or Asian girls.
Age at diagnosis was lowest in Black African/
Caribbean patients (12.34 years) when compared to
White Caucasian (13.06 years) or Asian (13.02 years)
patients, however, age at symptom onset did not vary
between groups, suggesting that Black African/
Caribbean patients were diagnosed sooner when com-
pared to other ethnicities. This observation may relate
to i) more severe disease phenotypes with increased dis-
ease activity and/or damage, ii) more classical appear-
ance of SLE typical symptoms in this sub-cohort, iii)
increased awareness among health care providers that
SLE occurs more frequently in Black African/
Caribbean patients and/or iv) higher rates of ANA pos-
itivity in Black African/Caribbean patients (although
this did not reach significance).
Somewhat surprisingly, White Caucasian jSLE
patients had more active disease at diagnosis when
compared to Asian or Black African/Caribbean
patients, as measured by SLEDAI scores. Using the
more detailed pBILAG scoring tool, White Caucasian
and Asian jSLE patients similarly showed increased
disease activity at diagnosis when compared to Black
African/Caribbean children, particularly affecting the
constitutional, mucocutaneous and musculoskeletal
BILAG domains.
Another explanation for the reduced numbers of
ANA and/or anti-dsDNA positive patients, increased
numbers of male patients and higher disease activity at
diagnosis (as measured by SLEDAI and pBILAG)
among White Caucasians may be an increased percent-
age of individuals with “atypical” and/or “monogenic”
disease.1,31 Patients with e.g. primary type I interfero-
nopathies, complement deficiencies, etc. can show early
disease onset, atypical clinical and laboratory features
(e.g. the absence of autoantibodies), and/or increased
disease activity which can change over time to a more
classical picture mimicking jSLE.6,32 Thus, differences
between ethnicities may be somewhat age dependent.
Indeed, later during the disease course, disease activity
(as measure by SLEDAI and pBILAG) did not vary
significantly between ethnicity groups. At last visit,
comparable disease activity and organ damage scores
were documented across ethnicity groups. When limit-
ing analysis to jSLE patients who were ANA positive at
diagnosis, findings largely remained (exception of ESR
with trends remaining). However, as the number of
ANA negative individuals was limited, no final and
reliable conclusion on the underlying disease patho-
physiology can be drawn. Thus, while it may well
explain clinical and laboratory differences between
age groups and ethnicities, increased numbers of mono-
genic forms of SLE in younger age groups and White
Caucasian jSLE sub-cohorts currently remains specu-
lative and will be addressed in large-scale genotyping
studies currently performed in the UK jSLE Cohort
Study.
While overall disease activity and damage scores do
not vary at last visit, several differences in organ system
involvement remain. During the disease course, Asian
jSLE patients exhibit more constitutional symptoms,
and Black African/Caribbean more frequently develop
haematological disease when compared to others.
Furthermore, there is a trend towards more renal
involvement in Black African/Caribbean jSLE patients
that fails to meet statistical significance (p¼ 0.06),
which reflects findings in adult cohorts.33,34 Variable
organ patterns may influence choice of treatment and
associated toxicity.35,36 Indeed, Asian and Black
African/Caribbean jSLE patients more frequently
received MMF when compared to White Caucasian
jSLE patients. Rituximab (p¼ 0.03) and cyclophospha-
mide (p¼ 0.027) were more frequently used in Black
African/Caribbean children when compared to other
ethnicity groups. Treatment choice may likely reflect
differences in organ involvement, and contribute to
more commonly occurring gonadal failure (p¼ 0.052)
in Back African/Caribbean jSLE patients.
The main limitation of this study relates to the sta-
tistical power, with approximately 700 participants
being required per group for ninety percent power to
be achieved, as per a previous study carried out on the
same cohort.6 However, this is not achievable in a rare
disease such as jSLE, even when national cohort data
are accessed, therefore, international collaboration is
warranted. Furthermore, the ethnicity data which is
collected by the UK jSLE Cohort is limited to the
patient/parent reported ethnicity and does not go
back to earlier generations.
Conclusions
Ethnicity affects clinical courses and disease outcomes
in jSLE. At diagnosis, Black African/Caribbean jSLE
patients show more “classical” laboratory and clinical
features when compared to White Caucasian or Asian
patients. Black African/Caribbean jSLE patients more
frequently exhibit renal involvement during the course
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of disease requiring stronger immunosuppression,
including cyclophosphamide that may itself contribute
to damage. At diagnosis, White Caucasian jSLE
patients exhibit less “typical” clinical and laboratory
patterns, including the absence of autoantibodies.
This may contribute to diagnostic delay and be
caused by increased prevalence of genetic forms of
SLE/SLE-like disease. Studies targeting potentially
ethnicity-specific genetic contributors to disease expres-
sion and phenotype are necessary to answer questions
remaining.
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